RecruitingPhase 2NCT06014775
Anti-CD38 Antibody Treating Evans Syndrome
Studying Evans syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Principal Investigator
- Lei Zhang, M.DInstitute of Hematology & Blood Diseases Hospital, China
- Intervention
- Anti-CD38 antibody Injection(drug)
- Enrollment
- 10 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06014775 on ClinicalTrials.govOther trials for Evans syndrome
Additional recruiting or active studies for the same condition.